Literature DB >> 20878357

An information-theoretic approach to surrogate-marker evaluation with failure time endpoints.

Assam Pryseley1, Abel Tilahun, Ariel Alonso, Geert Molenberghs.   

Abstract

Over the last decades, the evaluation of potential surrogate endpoints in clinical trials has steadily been growing in importance, not only thanks to the availability of ever more potential markers and surrogate endpoints, also because more methodological development has become available. While early work has been devoted, to a large extent, to Gaussian, binary, and longitudinal endpoints, the case of time-to-event endpoints is in need of careful scrutiny as well, owing to the strong presence of such endpoints in oncology and beyond. While work had been done in the past, it was often cumbersome to use such tools in practice, because of the need for fitting copula or frailty models that were further embedded in a hierarchical or two-stage modeling approach. In this paper, we present a methodologically elegant and easy-to-use approach based on information theory. We resolve essential issues, including the quantification of "surrogacy" based on such an approach. Our results are put to the test in a simulation study and are applied to data from clinical trials in oncology. The methodology has been implemented in R.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20878357     DOI: 10.1007/s10985-010-9185-6

Source DB:  PubMed          Journal:  Lifetime Data Anal        ISSN: 1380-7870            Impact factor:   1.588


  20 in total

1.  Surrogate markers in AIDS: where are we? Where are we going?

Authors:  S W Lagakos; D F Hoth
Journal:  Ann Intern Med       Date:  1992-04-01       Impact factor: 25.391

2.  Explained randomness in proportional hazards models.

Authors:  John O'Quigley; Ronghui Xu; Janez Stare
Journal:  Stat Med       Date:  2005-02-15       Impact factor: 2.373

Review 3.  Information-theory based surrogate marker evaluation from several randomized clinical trials with continuous true and binary surrogate endpoints.

Authors:  Assam Pryseley; Abel Tilahun; Ariel Alonso; Geert Molenberghs
Journal:  Clin Trials       Date:  2007       Impact factor: 2.486

4.  Surrogate marker evaluation from an information theory perspective.

Authors:  Ariel Alonso; Geert Molenberghs
Journal:  Biometrics       Date:  2007-03       Impact factor: 2.571

5.  Quantification of the prentice criteria for surrogate endpoints.

Authors:  John O'Quigley; Philippe Flandre
Journal:  Biometrics       Date:  2006-03       Impact factor: 2.571

6.  Explained variation in survival analysis.

Authors:  M Schemper; J Stare
Journal:  Stat Med       Date:  1996-10-15       Impact factor: 2.373

7.  Surrogate endpoints in clinical trials: definition and operational criteria.

Authors:  R L Prentice
Journal:  Stat Med       Date:  1989-04       Impact factor: 2.373

8.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1989-08-10       Impact factor: 91.245

9.  Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.

Authors:  Daniel J Sargent; Harry S Wieand; Daniel G Haller; Richard Gray; Jacqueline K Benedetti; Marc Buyse; Roberto Labianca; Jean Francois Seitz; Christopher J O'Callaghan; Guido Francini; Axel Grothey; Michael O'Connell; Paul J Catalano; Charles D Blanke; David Kerr; Erin Green; Norman Wolmark; Thierry Andre; Richard M Goldberg; Aimery De Gramont
Journal:  J Clin Oncol       Date:  2005-10-31       Impact factor: 44.544

10.  A unifying approach for surrogate marker validation based on Prentice's criteria.

Authors:  Ariel Alonso; Geert Molenberghs; Helena Geys; Marc Buyse; Tony Vangeneugden
Journal:  Stat Med       Date:  2006-01-30       Impact factor: 2.373

View more
  4 in total

1.  A Study of R2 Measure under the Accelerated Failure Time Models.

Authors:  Priscilla H Chan; Ronghui Xu; Christina D Chambers
Journal:  Commun Stat Simul Comput       Date:  2018-01-01       Impact factor: 1.118

2.  Three measures of explained variation for correlated survival data under the proportional hazards mixed-effects model.

Authors:  Gordon Honerkamp-Smith; Ronghui Xu
Journal:  Stat Med       Date:  2016-05-30       Impact factor: 2.373

Review 3.  Endoscopic ulcers as a surrogate marker of NSAID-induced mucosal damage.

Authors:  R Andrew Moore
Journal:  Arthritis Res Ther       Date:  2013-07-24       Impact factor: 5.156

4.  Evaluation of surrogacy in the multi-trial setting based on information theory: an extension to ordinal outcomes.

Authors:  Hannah Ensor; Christopher J Weir
Journal:  J Biopharm Stat       Date:  2019-12-30       Impact factor: 1.051

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.